Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients
Not Applicable
Recruiting
- Conditions
- on small cell lung cancer
- Registration Number
- JPRN-UMIN000044811
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients with active multiple cancers (hormonal therapy for prostate cancer and breast cancer is acceptable) (2)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with positive driver gene mutations and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable) (3)Other patients who are judged inappropriate by the physician in charge.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method